Bullous pemphigoid during ustekinumab therapy

Guern, A. Le; Alkeraye, Salim; Vermersch‐Langlin, A.; Coupé, Patrick; Vonarx, M.

doi:10.1016/j.jdcr.2015.07.014

Cited by 30 publications

(27 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of ustekinumab in psoriasis is associated with an excellent safety profile. However, isolated reports exist of immune-mediated adverse events in patients treated with this drug: cases of small vessel vasculitis, 8 bullous pemphigoid,9, 10, 11 and linear IgA bullous dermatosis 12 have been described. These cases indicate that antibody-antigen complex disease (vasculitis) and loss of B-cell tolerance with autoantibody-mediated disease (immune-bullous disease) may occur in patients undergoing IL-12 and IL-23 inhibition (Table I).…”

Section: Discussionmentioning

confidence: 99%

New-onset autoantibody-mediated nephritis during ustekinumab therapy for psoriasis in patients with and without prior systemic lupus erythematosus

2019

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

New-onset autoantibody-mediated nephritis during ustekinumab therapy for psoriasis in patients with and without prior systemic lupus erythematosus

2019

View full text Add to dashboard Cite

“…After reviewing the literature, we found 22 cases of anti‐inflammatory BA‐induced AIBD, which are summarized in Table . We identified three additional cases suspicious for the development of AIBD following treatment with such agents as secukinumab, infliximab, and golimumab, which were ultimately excluded due to lack of diagnostic criteria to diagnose a specific AIBD.…”

Section: Resultsmentioning

confidence: 99%

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

Gibson

Amber

2019

Int J Dermatology

View full text Add to dashboard Cite

Background To investigate the clinical course of autoimmune blistering diseases (AIBDs) following treatment with biologic agents (BAs) for chronic inflammatory diseases.Methods A comprehensive review of available, published literature was performed using PubMed and CINAHL search engines. Diagnostic criteria of AIBD included positive direct immunofluorescence studies and/or positive serology with clinically suggestive features.Results A total of 22 cases of AIBDs provoked by the use of BAs were found. The most commonly implicated agents were tumor necrosis factor-alpha inhibitors (n = 14). The mean age of onset of AIBD was 59.4 years (median 61.5 years, range 31-82). Average time to onset of AIBD following initiation of the suspected BA was 33.7 AE 43.8 weeks (range 3 days to 152 weeks). Psoriasis was the most common associated condition for which the BA was prescribed (n = 11), followed by rheumatoid arthritis (n = 6) and ulcerative colitis (n = 5). Of the 21 cases reporting AIBD outcome, 17 reported remission or complete resolution upon stopping treatment with the involved BA. Four cases reported continued bullae formation without worsening of disease following cessation of the BA or systemic corticosteroids used to treat the AIBD. Five cases rechallenged the patient with the involved BA and four of the five reported recurrence, often with quicker onset and more severe symptoms.Conclusions BAs may be suspected in patients developing AIBD while being treated for chronic inflammatory diseases. A majority of cases resolve upon cessation of the offending agent.

show abstract

“…Such reactions include cellulitis, herpes zoster, lymphomatoid drug eruption, urticaria, injection site reactions, recurrent erythema annulare centrifugum, bullous pemphigoid, erythema multiforme, and eczematous drug eruptions. [3][4][5][6][7][8] Drugs frequently associated with fixed drug eruption include antibacterial agents (trimethoprim-sulfamethoxazole, tetracyclines, penicillins, quinolones, and dapsone), nonsteroidal anti-inflammatory drugs (acetylsalicylic acid, ibuprofen, naproxen, and mefenamic acid), acetaminophen (paracetamol), barbiturates, antimalarials (quinine), and anticonvulsants (carbamazepine). 1 Our patient presented with fixed drug eruption induced by ustekinumab.…”

Section: Discussionmentioning

confidence: 99%